serdexmethylphenidate   Click here for help

GtoPdb Ligand ID: 11450

Synonyms: Azstarys® (serdexmethylphenidate + dexmethylphenidate) | KP-484 | KP484
Approved drug
serdexmethylphenidate is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Serdexmethylphenidate (KP484) is a prodrug that is a slow-release derivative of dexmethylphenidate (d-MPH).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 149.18
Molecular weight 499.2
XLogP 1.85
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC[C@@H](C(=O)[O-])NC(=O)c1ccc[n+](c1)COC(=O)N1CCCC[C@@H]1[C@@H](c1ccccc1)C(=O)OC
Isomeric SMILES OC[C@@H](C(=O)[O-])NC(=O)c1ccc[n+](c1)COC(=O)N1CCCC[C@@H]1[C@@H](c1ccccc1)C(=O)OC
InChI InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/t19-,20+,21+/m0/s1
InChI Key UBZPNQRBUOBBLN-PWRODBHTSA-N
No information available.
Summary of Clinical Use Click here for help
Serdexmethylphenidate in combination with dexmethylphenidate was approved by the FDA in March 2021 as a treatment for ADHD in children ≥6 years old. The orally administered fixed dose combination was known as KP415 during the development process. Serdexmethylphenidate has a delayed onset and prolonged duration of effects, so acts as a long-acting psychostimulant, whilst dexmethylphenidate provides a more rapid onset of action.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03460652 KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD Phase 3 Interventional KemPharm, Inc.